SCHEMBL5377705

SCHEMBL5377705

[c]1ccc(-c2n[nH]c3ccc(-c4nc[nH]n4)cc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.43
MAP2K4 P45985 8/20 0.40
MAPK1 P28482 5/20 0.40
MAPKAPK3 Q16644 5/20 0.40
MAPK6 Q16659 5/20 0.40
MAPKAPK2 P49137 3/20 0.40
MAPKAPK5 Q8IW41 2/20 0.40
TTK P33981 3/20 0.40
CSNK1D P48730 2/20 0.39
DCLK1 O15075 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39
CSF1R P07333 1/20 0.39
FER P16591 1/20 0.39
CDK2 P24941 1/20 0.39
MARK3 P27448 1/20 0.39
FLT4 P35916 1/20 0.39
FLT3 P36888 1/20 0.39
MAPK9 P45984 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14514472 0.86 MKNK1 (0.60) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5073584 0.84 CSNK1D (0.51) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5381923 0.84 FGFR1 (0.46) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5374429 0.84 MAP2K4 (0.55) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5378044 0.84 MKNK1 (0.44) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5372930 0.83 MKNK1 (0.49) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL8268311 0.82 PRKAG1 (0.49) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5381579 0.81 NTRK1 (0.44) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5381918 0.80 MAP2K4 (0.64) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL5378750 0.80 TTK (0.62) MKNK1MAP2K4MAPK1MAPKAPK3MAPK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7211594-B2 Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith SIGNAL PHARMACEUTICALS, LLC (US) 2007-05-01 US disclosed
US-20050261365-A1 Transthyretin stabilization THE SCRIPPS RESEARCH INSTITUTE (US) 2005-11-24 US disclosed
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261365-A1 Transthyretin stabilization TTR, TTPA, ALB MKNK1 3308/4885MAP2K4 4261/4885MAPK1 3603/4885
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R MKNK1 65/4885MAP2K4 385/4885MAPK1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.